AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22081113 — intervention group
Group type: COMPARATOR
Intervention: Control (loss of resistance or hanging drop technique)
Number of subjects: 80
Study 21108431 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular Resonance (MR)
Number of subjects: 96
Study 21108431 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar Cautery (MPC)
Number of subjects: 96
Study 21108431 — intervention group
Group type: COMPARATOR
Intervention: Coblation (CAT)
Number of subjects: 96
Study 18202666 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day for 12 weeks
Number of subjects: 60
Study 18202666 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 60
Study 16457423 — intervention group
Group type: EXPERIMENTAL
Intervention: Active relaxation
Number of subjects: 58
Study 16457423 — intervention group
Group type: COMPARATOR
Intervention: Passive relaxation
Number of subjects: 58
Study 13130405 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin; specific dosage and duration not mentioned.
Number of subjects: 0
Study 13130405 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10836915 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (160 mg or 800 mg)
Number of subjects: 42
Study 10836915 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg)
Number of subjects: 42
Study 10836915 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (prophylaxis)
Number of subjects: 42
Study 10836915 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (prophylaxis)
Number of subjects: 42
Study 8862238 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal blood pressure control
Number of subjects: 665
Study 8862238 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 665
Study 1611641 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef (400 mg twice daily)
Number of subjects: 488
Study 1611641 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (500/125 mg three times daily)
Number of subjects: 488
Study 1611641 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef
Number of subjects: 488
Study 1611641 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 488
Study 29679416 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial culture sampling at pre-, intra-, and post-operative time points
Number of subjects: 31
Study 29679416 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of bacterial isolates including MRSA and ESBL-producers
Number of subjects: 31
Study 29679416 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of bacterial contamination and its relation to SSI
Number of subjects: 31
Study 28654918 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg b.i.d.
Number of subjects: 18
Study 28654918 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg b.i.d.
Number of subjects: 18
Study 26472682 — intervention group
Group type: EXPERIMENTAL
Intervention: HFpEF
Number of subjects: 570
Study 26472682 — intervention group
Group type: EXPERIMENTAL
Intervention: HFrEF
Number of subjects: 570
Study 26472682 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined biomarkers
Number of subjects: 570
Study 26472682 — intervention group
Group type: COMPARATOR
Intervention: Cystatin-C
Number of subjects: 570
Study 26472682 — intervention group
Group type: COMPARATOR
Intervention: NT-proBNP
Number of subjects: 570
Study 23747790 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 7141
Study 23747790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7141
Study 23747790 — intervention group
Group type: COMPARATOR
Intervention: Nesiritide and Placebo
Number of subjects: 7141
Study 21402642 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified mother's milk (group B)
Number of subjects: 320
Study 21402642 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfortified mother's milk (group A)
Number of subjects: 320
Study 21402642 — intervention group
Group type: COMPARATOR
Intervention: Preterm formula (group C)
Number of subjects: 320
Study 19951447 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g once a day
Number of subjects: 3161
Study 19951447 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin/tazobactam (recommended dose)
Number of subjects: 3161
Study 17535624 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ferrous sulphate 200 mg TDS for 2 weeks pre-operatively
Number of subjects: 49
Study 17535624 — intervention group
Group type: COMPARATOR
Intervention: No iron therapy
Number of subjects: 49
Study 14566032 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic tape (patellar realignment and soft-tissue unloading)
Number of subjects: 105
Study 14566032 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo) tape and no tape
Number of subjects: 105
Study 11445676 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate culture (H0)
Number of subjects: 68
Study 11445676 — intervention group
Group type: COMPARATOR
Intervention: Delayed culture (H24)
Number of subjects: 68
Study 12515413 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational video package intervention
Number of subjects: 115
Study 12515413 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-counseling intervention
Number of subjects: 115
Study 12515413 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (motivational video and peer counseling)
Number of subjects: 115
Study 12515413 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 115
Study 8035916 — intervention group
Group type: EXPERIMENTAL
Intervention: IV penicillin G (3 g q 6 h)
Number of subjects: 54
Study 8035916 — intervention group
Group type: COMPARATOR
Intervention: Oral doxycycline (200 mg q 24 h)
Number of subjects: 54
Study 3141219 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 micrograms norgestimate
Number of subjects: 16
Study 3141219 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 micrograms norgestimate
Number of subjects: 16
Study 3141219 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study 31794039 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamification intervention in nursing education
Number of subjects: 191
Study 31794039 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gamification)
Number of subjects: 191
Study 28422462 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips Sonicare DiamondClean with Premium plaque control brush head (SPC)
Number of subjects: 284
Study 28422462 — intervention group
Group type: COMPARATOR
Intervention: Oral-B 7000 with CrossAction brush head (OCA)
Number of subjects: 284
Study 26463446 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) at 1 Hz for 20 sessions to the temporoparietal junction ipsilateral to the symptomatic ear.
Number of subjects: 0
Study 26463446 — intervention group
Group type: COMPARATOR
Intervention: Standard corticosteroid therapy (SCT) and hyperbaric oxygen (HBO) therapy without rTMS.
Number of subjects: 0
Study 26463446 — intervention group
Group type: EXPERIMENTAL
Intervention: Single photon emission computed tomography (SPECT) measurements in a subgroup of patients receiving rTMS.
Number of subjects: 0
Study 23628132 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin D3 weekly for 8 weeks
Number of subjects: 160
Study 23628132 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin supplement containing 400 IU vitamin D3/d
Number of subjects: 160
Study 21342321 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 32
Study 21342321 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol
Number of subjects: 32
Study 19644396 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 98
Study 19644396 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 98
Study 17388703 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic drug treatment
Number of subjects: 1708
Study 15041583 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 34
Study 15041583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 11720431 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel formulated in polysorbate 80
Number of subjects: 6
Study 11720431 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel formulated in Cremophor EL 15 ml m(‐2)
Number of subjects: 6
Study 9205939 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (n = 9)
Number of subjects: 34
Study 9205939 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril (n = 25)
Number of subjects: 34
Study 9205939 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 29 controls)
Number of subjects: 34
Study 7835804 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for ovarian cancer
Number of subjects: 0
Study 7835804 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 3295122 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (500 mg)
Number of subjects: 50
Study 3295122 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 50
Study 31108869 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided crockery set (sector plate, calibrated bowl, and calibrated glass)
Number of subjects: 29
Study 31108869 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibrated serving spoons (one for starch, one for protein, and one for vegetables)
Number of subjects: 29
Study 31108869 — intervention group
Group type: EXPERIMENTAL
Intervention: Both portion-control tools
Number of subjects: 29
Study 28634173 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutter device
Number of subjects: 40
Study 28634173 — intervention group
Group type: COMPARATOR
Intervention: Lung Flute device
Number of subjects: 40
Study 25459563 — intervention group
Group type: EXPERIMENTAL
Intervention: Six freeze-thaw cycles on sputum samples
Number of subjects: 8
Study 25459563 — intervention group
Group type: EXPERIMENTAL
Intervention: Three freeze-thaw cycles on sputum samples
Number of subjects: 8
Study 24683770 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride
Number of subjects: 42
Study 24683770 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP
Number of subjects: 42
Study 24683770 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP with fluoride
Number of subjects: 42
Study 24683770 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP with ozone
Number of subjects: 42
Study 24683770 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP without ozone
Number of subjects: 42
Study 21206418 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid for 14 days
Number of subjects: 282
Study 21206418 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg bid and amoxicillin 1 g bid for 7 days, followed by metronidazole 500 mg bid, tetracycline 500 mg qid, and lansoprazole 30 mg bid for an additional 7 days
Number of subjects: 282
Study 19201400 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 0
Study 19201400 — intervention group
Group type: COMPARATOR
Intervention: Folic Acid (FA)
Number of subjects: 0
Study 17460497 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (12.5 mg zinc sulfate tablet daily for about 6 months)
Number of subjects: 686
Study 17460497 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 686
Study 16305600 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ATP1A1 subunit of the ATPase gene mRNA expression in CP
Number of subjects: 30
Study 16305600 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP1A1 subunit expression in Andeans in Lima
Number of subjects: 30
Study 16305600 — intervention group
Group type: COMPARATOR
Intervention: Andean controls in Lima
Number of subjects: 30
Study 11956122 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine SR 1.5 mg BID
Number of subjects: 268
Study 11956122 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine SR (0.3, 0.6, 0.9, 1.2, or 1.5 mg BID)
Number of subjects: 268
Study 11956122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study 11956122 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine SR
Number of subjects: 268
Study 9607349 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) model
Number of subjects: 95
Study 9607349 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic Regression (LR) model
Number of subjects: 95
Study 9607349 — intervention group
Group type: COMPARATOR
Intervention: Staging model
Number of subjects: 95
Study 8549952 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa 2a (3 million units, three times a week for 52 weeks)
Number of subjects: 70
Study 8549952 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa 2a (3 million units, three times a week for 8 weeks)
Number of subjects: 70
Study 8549952 — intervention group
Group type: COMPARATOR
Intervention: Placebo (8 weeks)
Number of subjects: 70
Study 2194987 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine 25 mg
Number of subjects: 0
Study 2194987 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine 50 mg
Number of subjects: 0
Study 2194987 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine 100 mg
Number of subjects: 0
Study 486862 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentives
Number of subjects: 0
Study 486862 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise during learning
Number of subjects: 0
Study 31693078 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 month of dual antiplatelet therapy (DAPT) followed by 23 months of ticagrelor monotherapy
Number of subjects: 15991
Study 31693078 — intervention group
Group type: COMPARATOR
Intervention: 12 months of DAPT followed by 12 months of aspirin monotherapy
Number of subjects: 15991
Study 31693078 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT
Number of subjects: 15991
Study 31661439 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous Laser Ablation (EVLA) with 1470 nm diode laser
Number of subjects: 50
Study 31661439 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency Ablation (RFA) with bipolar Radiofrequency Induced Thermotherapy
Number of subjects: 50
Study 28577272 — intervention group
Group type: EXPERIMENTAL
Intervention: ADV6209 (15 mg, oral)
Number of subjects: 12
Study 28577272 — intervention group
Group type: COMPARATOR
Intervention: Midazolam hydrochloride intravenous solution (5 mg, i.v.)
Number of subjects: 12
Study 25813411 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-daily (TID) U‐500R insulin
Number of subjects: 325
Study 25813411 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily (BID) U‐500R insulin
Number of subjects: 325
Study 23816977 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 20% hydroxypropyl‐β‐cyclodextrin (2‐HPβCD) in a polyethylene glycol (PEG) formulation, applied twice daily for 6 months.
Number of subjects: 40
Study 23816977 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control (PEG formulation without 2‐HPβCD), applied twice daily for 6 months.
Number of subjects: 40
Study 21999413 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 27
Study 21999413 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol tartrate
Number of subjects: 27
Study 21999413 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol succinate
Number of subjects: 27
Study 21999413 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol, Metoprolol tartrate, Metoprolol succinate
Number of subjects: 27
Study 19589851 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapist-directed exercise counseling plus fitness center-based exercise training
Number of subjects: 24
Study 19589851 — intervention group
Group type: COMPARATOR
Intervention: Laboratory-based, supervised exercise
Number of subjects: 24
Study 16492824 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 40 mg sublingually 2 hours before surgery
Number of subjects: 52
Study 16492824 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 40 mg sublingually 10 minutes after surgery (Control)
Number of subjects: 52
Study 15075512 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) 200/100 mg
Number of subjects: 100
Study 15075512 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) 400/100 mg
Number of subjects: 100
Study 15075512 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) 400/200 mg
Number of subjects: 100
Study 15075512 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) open-label 400/100 mg
Number of subjects: 100
Study 15075512 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 100
Study 11297963 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO)
Number of subjects: 0
Study 11297963 — intervention group
Group type: COMPARATOR
Intervention: Contemporary conventional care
Number of subjects: 0
Study 9007492 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (systemic group) for 10 days
Number of subjects: 40
Study 9007492 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (inhaled group, 100 micrograms qds) for 10 days
Number of subjects: 40
Study 8373274 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B intravenously for 1 week postburn
Number of subjects: 76
Study 8373274 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 76
Study 3115153 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2 mg . kg‐1)
Number of subjects: 200
Study 3115153 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with Alfentanil (2 mg . kg‐1 propofol with 4 micrograms . kg‐1 alfentanil)
Number of subjects: 200
Study 3115153 — intervention group
Group type: COMPARATOR
Intervention: Ketamine with Midazolam (0.5 mg . kg‐1 ketamine with 0.25 mg . kg‐1 midazolam)
Number of subjects: 200
Study 3115153 — intervention group
Group type: COMPARATOR
Intervention: Ketamine with Midazolam (1 mg . kg‐1 ketamine with 0.1 mg . kg‐1 midazolam)
Number of subjects: 200
Study 3115153 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol groups
Number of subjects: 200
Study 3115153 — intervention group
Group type: COMPARATOR
Intervention: Ketamine-Midazolam groups
Number of subjects: 200
Study 3115153 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 200
Study 29685017 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior hemivertebra resection in combination with screw rod internal fixation
Number of subjects: 115
Study 29685017 — intervention group
Group type: COMPARATOR
Intervention: Posterior hemivertebra resection only
Number of subjects: 115
Study 27010115 — intervention group
Group type: EXPERIMENTAL
Intervention: PPS 100 mg thrice daily
Number of subjects: 32
Study 27010115 — intervention group
Group type: EXPERIMENTAL
Intervention: PPS 100 mg once daily and placebo twice daily
Number of subjects: 32
Study 27010115 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin B complex tablet) thrice daily
Number of subjects: 32
Study 24532969 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg daily for 7 days
Number of subjects: 0
Study 24532969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23336539 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress group (Trier Social Stress Test)
Number of subjects: 0
Study 23336539 — intervention group
Group type: COMPARATOR
Intervention: No-stress control group
Number of subjects: 0
Study 21515737 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced disbelief in free will
Number of subjects: 0
Study 21515737 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 19064024 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 1832
Study 16503687 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist and forearm training (Group 2)
Number of subjects: 43
Study 16503687 — intervention group
Group type: COMPARATOR
Intervention: Full-body resistance exercises (Group 1)
Number of subjects: 43
Study 12949433 — intervention group
Group type: EXPERIMENTAL
Intervention: Music during endoscopy
Number of subjects: 301
Study 12949433 — intervention group
Group type: COMPARATOR
Intervention: No music during endoscopy
Number of subjects: 301
Study 10870071 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (8 mg/kg/day orally for 4 days) after 3 days of intravenous ceftriaxone (100 mg/kg/day) and amikacin (15 mg/kg/day)
Number of subjects: 128
Study 10870071 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone plus amikacin (for 7 days)
Number of subjects: 128
Study 10870071 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 128
Study 9100553 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH (rhGH; mean dose 2.4 IU daily)
Number of subjects: 20
Study 8096959 — intervention group
Group type: EXPERIMENTAL
Intervention: halofantrine (72 mg/kg)
Number of subjects: 114
Study 8096959 — intervention group
Group type: EXPERIMENTAL
Intervention: halofantrine (24 mg/kg, 3 doses)
Number of subjects: 114
Study 8096959 — intervention group
Group type: COMPARATOR
Intervention: mefloquine (25 mg/kg)
Number of subjects: 114
Study 3589701 — intervention group
Group type: EXPERIMENTAL
Intervention: alfa‐2b interferon (Intron A, Schering Corp, Kenilworth, NJ), 2 megaunits/m2, subcutaneously, three times a week
Number of subjects: 128
Study 3589701 — intervention group
Group type: COMPARATOR
Intervention: observation only
Number of subjects: 128
Study 3589701 — intervention group
Group type: COMPARATOR
Intervention: continued interferon therapy
Number of subjects: 128
Study 30268528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (2 mg/kg/h)
Number of subjects: 162
Study 30268528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 27376698 — intervention group
Group type: EXPERIMENTAL
Intervention: EX (exercise followed by no meal)
Number of subjects: 23